drugset

drugset / Trial / NCT00541996

Study Comparing Bioavailability of Oral Formulations of Vabicaserin

NCT00541996 ↗

Phase 1 Completed Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedCrossoverOpen-labelHealth-services research

Summary

The purpose of this study is to determine the absorption rate of four oral formulations of vabicaserin.

Timeline

Start: 2007-08
Primary completion: —
Completion: 2007-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	vabicaserin	Small molecule	—	Oral

Indications